In This Article:
Over the last 7 days, the United States market has dropped 1.0%, but it has risen by 38% over the past year, with earnings forecast to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on future opportunities.
Top 10 High Growth Tech Companies In The United States
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Super Micro Computer | 21.08% | 28.73% | ★★★★★★ |
Sarepta Therapeutics | 23.84% | 44.09% | ★★★★★★ |
TG Therapeutics | 28.39% | 43.54% | ★★★★★★ |
Invivyd | 42.91% | 70.39% | ★★★★★★ |
Ardelyx | 27.19% | 66.44% | ★★★★★★ |
Amicus Therapeutics | 20.26% | 62.89% | ★★★★★★ |
AsiaFIN Holdings | 60.53% | 81.55% | ★★★★★★ |
Travere Therapeutics | 29.24% | 70.69% | ★★★★★★ |
Seagen | 22.57% | 71.80% | ★★★★★★ |
ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 247 stocks from our US High Growth Tech and AI Stocks screener.
We'll examine a selection from our screener results.
aTyr Pharma
Simply Wall St Growth Rating: ★★★★★☆
Overview: aTyr Pharma, Inc. is a biotherapeutics company focused on discovering and developing medicines based on novel immunological pathways in the United States, with a market capitalization of $253.92 million.
Operations: Focused on novel immunological pathways, aTyr Pharma is engaged in the discovery and development of therapeutic medicines.
aTyr Pharma, recently added to the S&P Global BMI Index, is navigating a transformative phase with projected revenue growth of 73.6% annually, outpacing the US market's average of 8.9%. Despite its current unprofitability and a highly volatile share price over the past three months, the company is expected to turn profitable within three years, with earnings potentially growing by 65.7% per year. This growth trajectory is underscored by significant R&D investments aimed at pioneering developments in biotechnology—a sector where innovation directly correlates with market success. However, shareholders have experienced dilution over the past year, reflecting ongoing capital needs for its ambitious expansion plans.
-
Click here and access our complete health analysis report to understand the dynamics of aTyr Pharma.
-
Review our historical performance report to gain insights into aTyr Pharma's's past performance.
Simulations Plus
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Simulations Plus, Inc. specializes in creating software for drug discovery and development that leverages artificial intelligence and machine learning to model and predict molecular properties, with a market capitalization of approximately $685.27 million.
Operations: The company generates revenue through two primary segments: software sales, which contribute $40.44 million, and services, accounting for $26.54 million.